Dayton Therapeutics

Curated by Signal

Developer of therapeutics for cancer indications

Life Sciences Technologydaytontherapeutics.com

Overview

Developer of therapeutics for cancer indications. The company uses AI and data mining to identify and develop drugs for oncology indications. The company's lead compound is "Satraplatin", an intravenous platinum compound for the treatment of prostate cancer.

Key facts

Founded: 2020
Headquarters: Zug, Switzerland
Stage: Sign up to view
Industry: Life Sciences Technology

More on Vanberra Signal

Members only

Business overviewCore metrics and financials PeopleLeadership and key people Similar companiesPeers and competitors Deep AnalysisAI-generated strategic report

Competitors & similar companies

More Life Sciences Technology companies

NeuroPro
Developer of device for monitoring brain signals
Life Sciences TechnologyZurich, Switzerland
GDBspace
Provider of a web-based listing platform of molecules
Life Sciences TechnologyBasel, Switzerland
Scailyte
Artificial intelligence (AI) based single-cell data analysis for novel biomarker discovery
Life Sciences TechnologyLucerne, Switzerland

About Dayton Therapeutics

What does Dayton Therapeutics do?

Developer of therapeutics for cancer indications.

Where is Dayton Therapeutics headquartered?

Dayton Therapeutics is headquartered in Zug, Switzerland.

When was Dayton Therapeutics founded?

Dayton Therapeutics was founded in 2020.

Which sector is Dayton Therapeutics in?

Dayton Therapeutics operates in Life Sciences Technology.

Who are Dayton Therapeutics's competitors?

Companies similar to Dayton Therapeutics include NeuroPro, GDBspace, and Scailyte.